YARW
Yarrow Bioscience Inc
NASDAQ · Healthcare · Biotechnology · US
$19.98
+9.12%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -2.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.1%
- EBITDA
- +32.9%
- EBIT
- +31.8%
- Net income
- +33.5%
- EPS
- +33.8%
- Free cash flow
- +2.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026